E., Li, J
Recent studies indicate that DPP-4 inhibitors, including linagliptin, could potentially complement the effects of other CV protective agents such as metformin [208], angiotensin type 2 receptor blockers (ARB) [41, 209], statins, and SGLT2 inhibitors [210,211,212]
While Lilly expects a deceleration in pricing gains in the second half of the year as discounts related to saving cards annualize, the robust pricing power showcases the strength of Lillys wide moat
A healthy dose of vitamins and minerals to optimize your immunity, energy, and overall wellness
Yuan and a group of other researchers recently published a paper comparing the effectiveness of different GLP-1RAs
In the short term there is no doubt that this is a cost increase. The immediate cost tsunami associated with widespread uptake currently dwarfs measurable savings, even if clinical benefits may eventually emerge